ЛИХОРАДКА, АССОЦИИРОВАННАЯ С МЕТАЛЛОКОНСТРУКЦИЕЙ. КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ

Metal constructions can cause fever even after a few years post implantation. This paper describes a case of 27 year old female with a fever associated with titanium construction implanted for kyphoscoliosis. 3 years post-operatively she developed afever (up to 39°С) and associated back pain. Examination revealed a hepatomegaly and lymphadenopathy (cervical and inguinal groups). Other investigations showed: neutrophilic leukocytosis (16×109\L), thrombocytosis (620×109\L), elevation of the C-reactive protein (76 ng/ml), ESR (62 mm/h) and ferritin (1615 ng/ml). There were no features of infection, connective tissue disease or hemoblastosis. A short course of therapy with methylprednisolone led to transient improvement. The metal device was surgically removed which caused an immediate elimination of fever and subsequent resolution of leukocytosis, thrombocytosis, lymphadenopathy and hepatomegaly.Металлоконструкции могут быть причиной фебрильной лихорадки даже спустя много лет после установки. В статье приведено клиническое наблюдение ассоциации лихорадки с металлоконструкцией, установленной по поводу кифосколиоза. Пациентке в возрасте 27 лет установлена торакоабдоминальная металлоконструкция. Спустя 3 года появилась фебрильная лихорадка до 39°С, возобновилась боль по ходу позвоночника, также возникли и сохранялись в течение последующих 3 месяцев нейтрофильный лейкоцитоз до 16 тыс./мкл, тромбоцитоз до 620 тыс./мкл, повышение С-реактивного белка до 76 мг/л, СОЭ до 62 мм/ч, ферритина до 1615 нг/мл, гепатомегалия, шейная и паховая лимфаденопатия. Данных в пользу инфекции, коллагеноза, гемобластоза не выявлено. Короткий курс терапии метилпреднизолоном привел к временному улучшению общего самочувствия. Металлоконструкция была удалена. Лихорадка на следующий день после операции разрешилась. Тромбоцитоз, нейтрофильный лейкоцитоз, органомегалия и лимфаденопатия регрессировали позже

Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents

In this paper analysis of anemia correction efficacy in multiple myeloma patients was shown. Patients (n = 68) treated with epoetin alfa (recombinant erythropoietin (rEPO)) 150 IU/kg subcutaneously three times per week (no more 20 weeks) were included in the study group. Patients who did not receive erythropoiesis-stimulating therapy were included in the control group (n = 31). Patients in both groups received at least 3 courses of chemotherapy and continued to receive anticancer treatment during follow-up. Baseline hemoglobin level was 5.3 g/dl – 10.0 g/dl. The increase in hemoglobin level to normal range (≥ 12.0 g/dl) during ≤ 20 weeks was considered as positive therapy response. Positive response rate was higher in patients received epoetin alfa comparing with control group (64.7 % and 25.8 %, respectively; p &lt; 0.05). Transfusion dependence persisted in 6 from 19 study patients who received RBC transfusions along with rEPO therapy (31.6 %), whereas in 5 from 9 control group patients (55.6 %). In epoetin alfa group significant increase in reticulocytes count at 2–3 weeks of therapywas revealed: from 27.3 × 109/l to 64.9 × 109/l (in patients with positive response) and from 13.3 × 109/l to 25.1 × 109/l (in patients without response). Changes in the reticulocytes count in the control group were not revealed. Thus in patients with positive response reticulocytes level significantly increased to 3 weeks of therapy compared with negative response patients (37.6 × 109/l versus 11.8 × 109/l, respectively; p &lt; 0,05), it can be used as prognostic factors of rEPO response.</p

Fever associated with metal device. Case report

Metal constructions can cause fever even after a few years post implantation. This paper describes a case of 27 year old female with a fever associated with titanium construction implanted for kyphoscoliosis. 3 years post-operatively she developed afever (up to 39°С) and associated back pain. Examination revealed a hepatomegaly and lymphadenopathy (cervical and inguinal groups). Other investigations showed: neutrophilic leukocytosis (16×109\L), thrombocytosis (620×109\L), elevation of the C-reactive protein (76 ng/ml), ESR (62 mm/h) and ferritin (1615 ng/ml). There were no features of infection, connective tissue disease or hemoblastosis. A short course of therapy with methylprednisolone led to transient improvement. The metal device was surgically removed which caused an immediate elimination of fever and subsequent resolution of leukocytosis, thrombocytosis, lymphadenopathy and hepatomegaly

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients

At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as neutropenia and thrombocytopenia. The adverse events correction in these circumstances is vital. Recommendations for neutropenia and thrombocytopenia correction are proposed in this article. The basement and results of the use of granulocyte colony stimulating factor (G-CSF) and thrombopoietine receptor agonist for hematologic toxicities correction with clinical case are presented.</p

Secondary hemophagocytic syndrome in adult patients. Study of 91 patients

Background. Secondary hemophagocytic lymphohystiocytosis (sHLH) is a hyperinflammatory reaction provoked by some trigger (cancer, autoimmune or infection). The majority of affected patients are at high risk of fatal multiple organ failure without getting immunsupressive treatment.Objective. Clinical and laboratory profile of sHLH patients.Materials and methods. Retrospective study included clinical, instrumental and lab data from the 91 patients followed between June 2009 and June 2019. Diagnosis sHLH had been based on HLH-2004 and H-Score criteria. The analyzed parameters had been fever chart, liver and spleen enlargement, changes in the bone marrow; values levels of glutamic pyruvic transaminase, serum glutamic oxaloacetic transaminase, alkaline phosphatase, bilirubin, triglycerides, total ferritin with percentage of glycosylation. All patients with rheumatic disorders or malignancies had received either immunosuppressive or cytotoxic therapy. Febrile patients received anti-infective treatment according to the local routine protocols.Results. The data from 91 patients (41 male and 50 female) had been analyzed. Median age was 58 (2–90) years. The sHLH trigger-diseases spectrum included leukemia/lymphoma (n = 52), infection diseases (n = 11), autoimmune disorders (n = 5), allogenic bone marrow transplantation (n = 13), unidentified (n = 10). A fever with an unknown origin and refractory to antibacterial treatment had been observed in 87 (96 %) patients. Morphological hemophagocytic evidences in the bone marrow had been found in 83 %. Breath shortening, liver failure, neurologic disturbances, systemic effusions, rash, heart failure had been registered in 83 % patients. Detected splenomegaly presented in 56 %. Laboratory changes, median were as following: serum glutamic-pyruvic transaminase (alanine aminotransferase, SGPT) – 92 (39.2–1060.8) IU/L; serum glutamic oxaloacetic transaminase (aspartate aminotransferase, SGOT) – 105 (40–4177) IU/L; alkaline phosphatase – 225 (120.9–989) IU/L; bilirubin – 50.5 (22–559) µmol/L; triglycerides – 3.2 (1.95–8.6) mmol/L; total ferritin – 10000 (597–255000) ng/mL with glycosylation percentage – 20.45 (0–37.8) %. 71 patients received various of HLH-directed therapy courses. The overall survival rate was 27 %, median follow-up – 540 days.Conclusion. The main clinical and instrumental findings in sHLH are fever, refractory to anti-infective treatment, elevation of transaminases, serum alkaline phosphatase, triglycerides, total ferritine with low glycosylated fraction. Early diagnosing and immunesupression are the main factors of survival